Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
71.67
-0.66 (-0.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug
↗
November 10, 2025
Ionis' olezarsen cut triglycerides by up to 72% and reduced acute pancreatitis events by 85% in Phase 3 studies of severe hypertriglyceridemia.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 10, 2025
Via
Benzinga
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
November 10, 2025
Via
Benzinga
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
↗
November 10, 2025
Via
Benzinga
Earnings Scheduled For October 29, 2025
↗
October 29, 2025
Via
Benzinga
Ionis Pharmaceuticals Earnings Preview
↗
October 28, 2025
Via
Benzinga
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
November 08, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies
↗
November 07, 2025
The company remains confident in its other gene-editing product, which would treat a swelling disorder.
Via
Investor's Business Daily
Topics
Death
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
November 06, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease
↗
September 23, 2025
Via
Stocktwits
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys
↗
November 04, 2025
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam...
Via
Benzinga
Ionis (IONS) Q3 2025 Earnings Call Transcript
↗
October 30, 2025
Ionis (IONS) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
↗
October 30, 2025
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.
Via
Investor's Business Daily
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday
↗
October 30, 2025
Via
Benzinga
Ionis reports third quarter 2025 financial results and highlights progress on key programs
October 29, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
October 27, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
October 23, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
October 21, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares
↗
October 20, 2025
Via
The Motley Fool
31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know
↗
October 16, 2025
Via
Benzinga
Ionis to hold third quarter 2025 financial results webcast
October 16, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows Strong Growth Momentum and Technical Strength
↗
October 15, 2025
IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth.
Via
Chartmill
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
October 08, 2025
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...
Via
MarketMinute
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
↗
October 08, 2025
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.
Via
Investor's Business Daily
This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
↗
October 08, 2025
Via
Benzinga
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
October 07, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
September 23, 2025
From
Biogen Inc.
Via
GlobeNewswire
What Analysts Are Saying About Ionis Pharmaceuticals Stock
↗
September 23, 2025
Via
Benzinga
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
↗
September 22, 2025
Ionis reports positive pivotal study results for zilganersen in Alexander disease, showing gait speed benefits and strong safety data.
Via
Benzinga
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
September 22, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
